Clinical Trials in Seattle

Showing 2741-2760 of 9,312 trials

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

NCT00719888

This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic disease. Giving chemotherapy, such as cyclophosphamide and fludarabine, and TBI before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after transplant may stop this from happening.

Acute Biphenotypic LeukemiaAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+16 more

Fred Hutchinson Cancer Center135 participantsStarted Nov 2005

Aurora, Colorado, United States • Seattle, Washington, United States • Seattle, Washington, United States

RECRUITINGNA< 1 mile

Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)

NCT06212193

Early Feasibility Study to evaluate the safety and performance of the Innoventric Trillium™ Stent Graft in the treatment of severe or greater tricuspid regurgitation (TR).

Tricuspid RegurgitationTricuspid Regurgitation Functional

Innoventric LTD15 participantsStarted Aug 2024

Thousand Oaks, California, United States • Detroit, Michigan, United States • Rochester, Minnesota, United States +9 more locations

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)

Find Trials by Condition in Seattle

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Closed-loop Spinal Stimulation for Restoration of Upper Extremity Function After Spinal Cord Injury

A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.

TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer

Lipoic Acid for Progressive Multiple Sclerosis (MS)

Improving BP Control in Diverse Populations Using BP MAP

PROACTIVE-HF IDE Trial Heart Failure NYHA Class III

Maintenance NeuroStar Transcranial Magnetic Stimulation (TMS) in Patients With Major Depressive Disorder

A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression

A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis

Effectiveness and Safety of Restylane Lyft Lidocaine for Jawline Definition

Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria

Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer

MGD019 DART® Protein in Unresectable/Metastatic Cancer

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

An Epidemiological Study to Assess Performance of Using Healthcare Tools to Understand Genital Herpes Simplex Virus-2 (HSV-2) in Patients ≥ 18 Years of Age in the United States and Europe.

Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination